CJC-1295 without DAC + IPA Combo (10mg)

Optimized peptide blend for research on growth hormone modulation and peptide interaction.

• CJC-1295 without DAC is a short-acting analog of growth hormone–releasing hormone (GHRH 1–29), designed for controlled peptide studies.
• Combined with IPA (Ipamorelin), a selective secretagogue studied for complementary action on GH release through distinct receptor pathways.
• Independently verified for composition, purity, and consistency by Vanguard Laboratory.

CJC-1295 without DAC is a modified GHRH analog that maintains biological activity while exhibiting a shorter half-life compared to the DAC-bound form. Research demonstrates acute stimulation of pulsatile GH release in controlled environments

Ipamorelin (IPA) is a pentapeptide studied for its selectivity at the ghrelin receptor, promoting GH release without affecting cortisol or prolactin levels

When combined, CJC-1295 without DAC and IPA are often studied for potential synergistic effects on GH pulse frequency and amplitude in peptide research models

Regulatory Status: CJC-1295 and Ipamorelin are not FDA-approved for human or veterinary use. These peptides are supplied strictly for laboratory research applications